Clinical Research Associates, L.L.C., an affiliate of the Simons Foundation, has recently launched a randomized controlled trial to test the safety, tolerability and efficacy of arbaclofen in 16p11.2 BP4-BP5 deletion syndrome.
This blog post accompanies the “SFARI’s 2018 funding priorities” post. In it, the SFARI science team discusses the application and review process for 2018 Pilot and Research Awards.
Autism BrainNet is now distributing frozen and fixed postmortem brain tissue from individuals with autism spectrum and other neurodevelopmental disorders, as well as neurotypical individuals, for use in research studies. Researchers from all over the world are eligible to apply.
Matthew Goodwin, Matthew Siegel and colleagues found that data from a wearable biosensor can be used to accurately predict aggressive behavior up to one minute before it occurs.
Three recent studies – two by Kristopher Kahle and Igor Medina, and the third by Xin Tang, Mriganka Sur and Rudolf Jaenisch – explored regulatory mechanisms that modulate KCC2 function during development as well as ways to potentially therapeutically enhance the expression of this chloride cotransporter.
Autism BrainNet has launched its newly redesigned website. The updated platform has an improved look and feel and new navigation features for a more pleasant, effective and informative user experience.
SFARI announces the recipients of the Autism BrainNet Appreciation Award, a new honor that recognizes outstanding partners and collaborators for their dedication to advancing brain tissue research in autism.
Since launching in 2016, SPARK has driven scientific discovery in autism, building a cohort of over 280,000 individuals, including more than 100,000 children and adults with autism.
A number of SFARI Investigators, collaborators and Simons Foundation scientists will present their latest research findings at the American Society of Human Genetics (ASHG) 2021 Virtual Meeting, which will be held October 18–22.